Thus, SIRT1 acts as a positive regulator of EMT to influence the metastatic growth of prostate cancer cells, while SIRT1 overexpression serves as a potential therapeutic target to reverse EMT and defend against prostate cancer progression [17]. Here, SIRT1 is linked to prostate carcinoma.